Anavex life sciences announces uplisting to the nasdaq global select market®

New york, sept. 27, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that effective as of market open today, september 27, 2021, its shares of common stock have been approved for uplisting to the nasdaq global select market® and will continue trading under its current ticker symbol avxl.
AVXL Ratings Summary
AVXL Quant Ranking